• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Fonar Board of Directors Appoints Independent Director

    11/23/21 2:07:00 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email

    Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.

    Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered at all HMCA-managed and HMCA-owned facilities. That responsibility requires us to regularly interact with hundreds of payers, including commercial insurance carriers, Medicare and Medicaid, Workers' Compensation, and No-Fault carriers regarding a wide variety of matters, such as collection issues, credentialing, and negotiating participation agreements in coordination with the owners."

    Also, since HMCA arranges for professional liability coverage at all the sites and assists medical personnel, including radiologists and technologists, with their individual professional liability coverage, Mr. Collins will be helpful there as well. We are delighted to have him working with the board of directors."

    Dr. Raymond Damadian, Chairman of FONAR, added, "While we are saddened by the recent passing of Mr. Charles O'Data, a dear friend and very able member of the board of directors since February 1998, we are very pleased with the addition of Mr. Collins and look forward to working with him."

    Mr. Collins is a partner at Brownell Partners, PLLC. The practice specializes in the defense of New York Labor Law, premises liability, commercial transportation, products liability, wrongful death, and matters involving allegations of commercial and professional malpractice. The practice also deals with insurance coverage disputes and property damage subrogation cases.

    Mr. Collins earned his bachelor's degree from the State University of New York at Albany in 2002, after which he spent the next seven years in the insurance industry as an Excess and Surplus Lines underwriter and wholesale broker. Mr. Collins graduated magna cum laude from New York Law School in 2012, where he was a John Marshall Harlan Scholar and a staff editor for the New York Law School Law Review. In 2011, Mr. Collins served as a judicial intern at the Southern District of New York, in the chambers of the Honorable Paul A. Crotty.

    Upon graduation, Mr. Collins completed a Fellowship with the Corporation Counsel of the City of New York. He defended the City in a wide variety of general and municipal liability matters, including motor vehicle accidents, premises liability, and in the defense of police officers and other municipal actors for claims of civil rights violations brought under 42 USC. §1983.

    Mr. Collins then entered private practice as an insurance defense attorney where he handled all types of insurance defense cases from inception to resolution, including construction accidents, premises liability, and motor vehicle accidents.

    About FONAR

    FONAR, The Inventor of MR Scanning™, is located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often detects patient problems that other MRI scanners cannot because they are lie-down and "weightless" only scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while watching TV.

    FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body's neurologic system has been made possible first by FONAR's introduction of the MRI and now by this latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.

    FONAR's substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the central nervous system. FONAR's UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.

    UPRIGHT® and STAND-UP® are registered trademarks. The Inventor of MR Scanning™, CSP™, Multi-Position™, UPRIGHT RADIOLOGY™, The Proof is in the Picture™, pMRI™, CSF Videography™, and Dynamic™ are trademarks of FONAR Corporation.

    This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.

    Contact: Daniel Culver
    Director of Communications
    E-mail: [email protected]
    www.fonar.com

    The Inventor of MR Scanning™
    An ISO 9001 Company
    Melville, New York 11747
    Phone: (631) 694-2929
    Fax: (631) 390-1772

    #

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104857

    Get the next $FONR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fonar Announces Fiscal 2025 Financial Results for 3rd Quarter and Nine-Month Period

      Net Income increased 25% to $3.1 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Income from Operations for the quarter ended March 31, 2025 decreased 2% to $3.7 million as compared to the quarter ended March 31, 2024. Diluted Net Income Per Common Share Available to Common Stockholders increased 37% to $0.37 per share for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024.Total Revenues-Net increased 6% to $27.2 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Total Cash, Cash Equivalents and Short-Term Investments decreased 4% to $54.4 million at March 31, 2025 as compar

      5/15/25 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025

      MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.Cash and Cash Equivalents and Short-term Iinvestments decreased 5% to $53.7 million at December 31, 2024, versus the fiscal year ended June 30, 2024. Total Revenues-Net for the six-month period ended December 31, 2024, decreased by 3% to $49.9 million, and for the quarter ended December 31, 2024, decreased by 2% to $25.0

      2/18/25 7:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Fonar Corporation

      10-Q - FONAR CORP (0000355019) (Filer)

      5/15/25 2:14:54 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Fonar Corporation

      DEF 14A - FONAR CORP (0000355019) (Filer)

      4/7/25 3:03:53 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - FONAR CORP (0000355019) (Filer)

      2/19/25 4:16:47 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Leadership Updates

    Live Leadership Updates

    See more
    • FONAR Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

      3/20/23 11:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

      11/23/21 2:07:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      11/14/24 12:27:58 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      2/13/24 5:04:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

      SC 13G/A - FONAR CORP (0000355019) (Subject)

      2/13/24 4:05:17 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:41:44 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:16:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Financials

    Live finance-specific insights

    See more
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

      Total MRI scan volume at the HMCA-managed sites increased 7% to 49,451 scans for the quarter ended March 31, 2023 versus the corresponding quarter one year earlier. For the nine-month period ended March 31, 2023, 139,339 scans were performed as compared to 140,650 for the corresponding nine-month period one year ago.Net Income increased 37% to $4.5 million for the quarter ended March 31, 2023 and decreased 27% to $9.9 million for the nine-month period ended March 31, 2023. Diluted Net Income Per Common Share Available to Common Stockholders increased 72% to $0.55 for the third fiscal quarter ended March 31, 2023 and decreased 19% to $1.16 for the nine-month period ended March 31, 2023. Tota

      5/15/23 4:05:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2021 as Diluted EPS Increases 23%

      Total MRI scan volume at the HMCA-managed sites increased 7 % to 178,364 scans for the fiscal year ending June 30, 2021 as compared to the prior year.Total Revenues-Net increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Net Income increased 17% to $13.7 million for the fiscal year ended June 30, 2021 versus the previous fiscal year.Diluted Net Income per Common Share increased 23% to $1.45 for the fiscal year ended June 30, 2021 versus the previous fiscal year. Book Value Per Share increased by 6% to $20.41 per s

      9/28/21 7:30:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care